CA2622016A1 - Interferon lambda therapy for treatment of respiratory diseases - Google Patents
Interferon lambda therapy for treatment of respiratory diseases Download PDFInfo
- Publication number
- CA2622016A1 CA2622016A1 CA002622016A CA2622016A CA2622016A1 CA 2622016 A1 CA2622016 A1 CA 2622016A1 CA 002622016 A CA002622016 A CA 002622016A CA 2622016 A CA2622016 A CA 2622016A CA 2622016 A1 CA2622016 A1 CA 2622016A1
- Authority
- CA
- Canada
- Prior art keywords
- ifn
- lambda
- cells
- polypeptides
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000014150 Interferons Human genes 0.000 title claims abstract description 32
- 108010050904 Interferons Proteins 0.000 title claims abstract description 32
- 208000023504 respiratory system disease Diseases 0.000 title claims abstract description 23
- 229940079322 interferon Drugs 0.000 title claims abstract description 19
- 238000011282 treatment Methods 0.000 title description 18
- 238000002560 therapeutic procedure Methods 0.000 title description 4
- 208000006673 asthma Diseases 0.000 claims abstract description 105
- 230000003612 virological effect Effects 0.000 claims abstract description 36
- 230000005713 exacerbation Effects 0.000 claims abstract description 23
- 241000709661 Enterovirus Species 0.000 claims description 138
- 210000004027 cell Anatomy 0.000 claims description 112
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 88
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 84
- 229920001184 polypeptide Polymers 0.000 claims description 82
- 208000015181 infectious disease Diseases 0.000 claims description 74
- 230000014509 gene expression Effects 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 53
- 210000000424 bronchial epithelial cell Anatomy 0.000 claims description 45
- 241000700605 Viruses Species 0.000 claims description 43
- 238000004519 manufacturing process Methods 0.000 claims description 32
- 208000010668 atopic eczema Diseases 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 21
- 102000040430 polynucleotide Human genes 0.000 claims description 21
- 239000002157 polynucleotide Substances 0.000 claims description 21
- 230000000172 allergic effect Effects 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 241000712461 unidentified influenza virus Species 0.000 claims description 19
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 241000724205 Rice stripe tenuivirus Species 0.000 claims 1
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 abstract description 44
- 102100020990 Interferon lambda-1 Human genes 0.000 abstract description 43
- 206010061494 Rhinovirus infection Diseases 0.000 abstract description 23
- 230000009385 viral infection Effects 0.000 abstract description 22
- 208000036142 Viral infection Diseases 0.000 abstract description 7
- 101100508438 Mus musculus Ifnk gene Proteins 0.000 description 66
- 230000006698 induction Effects 0.000 description 64
- 108020004999 messenger RNA Proteins 0.000 description 53
- 229940047124 interferons Drugs 0.000 description 41
- 239000013615 primer Substances 0.000 description 40
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 36
- 208000024891 symptom Diseases 0.000 description 36
- 230000000241 respiratory effect Effects 0.000 description 31
- 210000002919 epithelial cell Anatomy 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 26
- 239000002609 medium Substances 0.000 description 26
- 102000003996 Interferon-beta Human genes 0.000 description 24
- 108090000467 Interferon-beta Proteins 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 23
- 239000000523 sample Substances 0.000 description 22
- 239000006228 supernatant Substances 0.000 description 22
- 102000006992 Interferon-alpha Human genes 0.000 description 21
- 108010047761 Interferon-alpha Proteins 0.000 description 21
- 230000004199 lung function Effects 0.000 description 21
- 230000004044 response Effects 0.000 description 21
- 229960001388 interferon-beta Drugs 0.000 description 19
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 16
- 102100040018 Interferon alpha-2 Human genes 0.000 description 16
- 230000000840 anti-viral effect Effects 0.000 description 16
- 108010018844 interferon type III Proteins 0.000 description 16
- 108020000999 Viral RNA Proteins 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 239000012634 fragment Substances 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 13
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 13
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 238000013276 bronchoscopy Methods 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 210000000038 chest Anatomy 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 12
- 241000725643 Respiratory syncytial virus Species 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 11
- 238000004448 titration Methods 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 10
- 201000004624 Dermatitis Diseases 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 239000002987 primer (paints) Substances 0.000 description 10
- 206010013975 Dyspnoeas Diseases 0.000 description 9
- 206010036790 Productive cough Diseases 0.000 description 9
- 206010047924 Wheezing Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229960001340 histamine Drugs 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000013125 spirometry Methods 0.000 description 9
- 208000024794 sputum Diseases 0.000 description 9
- 210000003802 sputum Anatomy 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 208000000059 Dyspnea Diseases 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 208000026935 allergic disease Diseases 0.000 description 8
- 230000014936 interferon-kappa production Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 241000709664 Picornaviridae Species 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 206010039085 Rhinitis allergic Diseases 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 201000010105 allergic rhinitis Diseases 0.000 description 7
- 230000007815 allergy Effects 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 238000007726 management method Methods 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- -1 9-fluorenylmethyloxycarbonyl (Fmoc) group Chemical group 0.000 description 6
- 206010003645 Atopy Diseases 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 108010014726 Interferon Type I Proteins 0.000 description 6
- 206010057190 Respiratory tract infections Diseases 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 208000013220 shortness of breath Diseases 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 description 5
- 208000037874 Asthma exacerbation Diseases 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 208000004262 Food Hypersensitivity Diseases 0.000 description 5
- 102000002227 Interferon Type I Human genes 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 208000037656 Respiratory Sounds Diseases 0.000 description 5
- 239000013566 allergen Substances 0.000 description 5
- 230000036783 anaphylactic response Effects 0.000 description 5
- 208000003455 anaphylaxis Diseases 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 201000009267 bronchiectasis Diseases 0.000 description 5
- 206010006451 bronchitis Diseases 0.000 description 5
- 229940124630 bronchodilator Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000020932 food allergy Nutrition 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 206010052613 Allergic bronchitis Diseases 0.000 description 4
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 4
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 4
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 4
- 208000016999 Parasitic Lung disease Diseases 0.000 description 4
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 229960004784 allergens Drugs 0.000 description 4
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000013116 chronic cough Diseases 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 201000009580 eosinophilic pneumonia Diseases 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 201000009240 nasopharyngitis Diseases 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 208000007892 occupational asthma Diseases 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000779 smoke Substances 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 108020004463 18S ribosomal RNA Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 3
- 208000034657 Convalescence Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 3
- 102100026720 Interferon beta Human genes 0.000 description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 3
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 3
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229940127225 asthma medication Drugs 0.000 description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000010083 bronchial hyperresponsiveness Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 208000010247 contact dermatitis Diseases 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000003748 differential diagnosis Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000013123 lung function test Methods 0.000 description 3
- 229920001427 mPEG Polymers 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 208000036273 reactive airway disease Diseases 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 206010011376 Crepitations Diseases 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000029662 T-helper 1 type immune response Effects 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013567 aeroallergen Substances 0.000 description 2
- 230000010085 airway hyperresponsiveness Effects 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 238000002555 auscultation Methods 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 230000036427 bronchial hyperreactivity Effects 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 230000008472 epithelial growth Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000010659 intrinsic asthma Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 238000009117 preventive therapy Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000001533 respiratory mucosa Anatomy 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 230000010472 type I IFN response Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical class CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- VUCNQOPCYRJCGQ-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenoxy]acetic acid Chemical class OCC1=CC=C(OCC(O)=O)C=C1 VUCNQOPCYRJCGQ-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 241000223602 Alternaria alternata Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 206010067182 Bronchial wall thickening Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 206010009126 Chronic respiratory failure Diseases 0.000 description 1
- 241001149956 Cladosporium herbarum Species 0.000 description 1
- 206010009691 Clubbing Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000583714 Homo sapiens Pleckstrin homology-like domain family A member 3 Proteins 0.000 description 1
- 101000694550 Homo sapiens RuvB-like 1 Proteins 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 102100040487 Keratin, type I cytoskeletal 13 Human genes 0.000 description 1
- 108010065070 Keratin-13 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108050005735 Maltoporin Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 102100027160 RuvB-like 1 Human genes 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- UATJOMSPNYCXIX-UHFFFAOYSA-N Trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UATJOMSPNYCXIX-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 208000000697 Vocal Cord Dysfunction Diseases 0.000 description 1
- 208000013154 Vocal cord disease Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000004544 dc2 Anatomy 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229940046528 grass pollen Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000057952 human IFNL1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- ZCQGVFNHUATAJY-UHFFFAOYSA-N methyl 2-[methyl(prop-2-enoyl)amino]acetate Chemical compound COC(=O)CN(C)C(=O)C=C ZCQGVFNHUATAJY-UHFFFAOYSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 240000004494 yellow birch Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0518425A GB0518425D0 (en) | 2005-09-09 | 2005-09-09 | Methods |
| GB0518425.4 | 2005-09-09 | ||
| US78329706P | 2006-03-17 | 2006-03-17 | |
| US60/783,297 | 2006-03-17 | ||
| PCT/GB2006/050281 WO2007029041A2 (en) | 2005-09-09 | 2006-09-08 | Interferon lambda therapy for treatment of respiratory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2622016A1 true CA2622016A1 (en) | 2007-03-15 |
Family
ID=37575101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002622016A Abandoned CA2622016A1 (en) | 2005-09-09 | 2006-09-08 | Interferon lambda therapy for treatment of respiratory diseases |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1922081B1 (enExample) |
| JP (1) | JP5172679B2 (enExample) |
| CA (1) | CA2622016A1 (enExample) |
| WO (1) | WO2007029041A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4094475B2 (ja) | 2003-04-21 | 2008-06-04 | 富士重工業株式会社 | 多気筒エンジンの燃焼圧データ収集システム |
| US7871603B2 (en) | 2007-05-18 | 2011-01-18 | Synairgen Research Limited | Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly |
| US8282964B2 (en) | 2007-10-27 | 2012-10-09 | Medical Diagnostic Laboratories, Llc | Ex-vivo treatment of peripheral plasmacytoid dendritic cells with IFN-lambda |
| US8354125B2 (en) | 2007-10-27 | 2013-01-15 | Grant Gallagher | Ex-vivo treatment of peripheral blood leukocytes with IFN-λ |
| EP2432898B1 (en) * | 2009-05-21 | 2014-11-26 | Merck Sharp & Dohme Corp. | Genetic markers associated with interferon-alpha response |
| HUE029250T2 (en) | 2010-03-12 | 2017-04-28 | Synairgen Res Ltd | For use in the treatment of interferon-beta, influenza-induced lower respiratory diseases |
| KR102096224B1 (ko) | 2011-10-28 | 2020-04-03 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
| WO2021245318A1 (es) * | 2020-06-04 | 2021-12-09 | Conicet - Consejo Nacional De Investigaciones Científicas Y Técnicas | Método para tratar infecciones del tracto respiratorio producidas por virus |
| US20220040265A1 (en) | 2020-08-07 | 2022-02-10 | Peter G. Carroll | Compositions and methods for preventing and/or inhibiting viral infection and spread |
| US20240181011A1 (en) * | 2020-11-04 | 2024-06-06 | Ethris Gmbh | Use of ifn-lambda mrna for treating viral infections |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040037809A1 (en) * | 2002-06-28 | 2004-02-26 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon beta |
| CA2543982C (en) * | 2003-11-07 | 2013-01-08 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| GB0405634D0 (en) * | 2004-03-12 | 2004-04-21 | Univ Southampton | Anti-virus therapy for respiratory diseases |
-
2006
- 2006-09-08 EP EP06779635A patent/EP1922081B1/en not_active Not-in-force
- 2006-09-08 WO PCT/GB2006/050281 patent/WO2007029041A2/en not_active Ceased
- 2006-09-08 CA CA002622016A patent/CA2622016A1/en not_active Abandoned
- 2006-09-08 JP JP2008529702A patent/JP5172679B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1119592A1 (en) | 2009-03-13 |
| EP1922081B1 (en) | 2012-08-15 |
| EP1922081A2 (en) | 2008-05-21 |
| WO2007029041A3 (en) | 2007-05-10 |
| JP5172679B2 (ja) | 2013-03-27 |
| WO2007029041A2 (en) | 2007-03-15 |
| JP2009514794A (ja) | 2009-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8273342B2 (en) | Anti-virus therapy for respiratory diseases | |
| Panina-Bordignon et al. | The CC chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics | |
| ES2645368T3 (es) | Terapias para mejorar la función pulmonar | |
| EP1922081B1 (en) | Interferon lambda therapy for treatment of respiratory diseases | |
| Garduno-Soto et al. | Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations | |
| JP2010502687A (ja) | 呼吸器疾患の治療方法 | |
| JP2023517616A (ja) | 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤 | |
| JP2022526524A (ja) | 喘息の処置のためのリポカリンムテイン | |
| CN101365474B (zh) | 用于治疗呼吸道疾病的干扰素λ疗法 | |
| CN115443126A (zh) | 用于预防或治疗SARS-CoV-2感染的相容性溶质 | |
| Julius et al. | Safety of segmental allergen challenge in human allergic asthma | |
| HK1119592B (en) | Interferon lambda therapy for treatment of respiratory diseases | |
| Zhao et al. | Osteopontin levels are elevated in patients with asthma | |
| WO2022024108A1 (en) | Ezrin peptide (hep-1) for use in the treatment of coronavirus disease | |
| JP2023513209A (ja) | インターフェロンラムダでのコロナウイルス感染の処置 | |
| KR20230041097A (ko) | SARS-CoV-2 감염 환자의 결과를 개선하기 위한 흡입형 인터페론-베타 | |
| AU2005336519B2 (en) | Method of treating pulmonary disease with interferons | |
| Shanmugavaradharajan et al. | Deteriorating Pulmonary Functions in Patients with Rheumatoid Arthritis-A Pilot Study from South India | |
| WO2022166885A1 (en) | Recombinant super-compound interferon (rsifn-co) for treating covid-19 patients with or without symptoms | |
| Branco et al. | Chronic respiratory failure in severe asthma–Questions answered after biological therapy, a clinical case | |
| EP4137209A1 (en) | Application of tff2 protein and ifn-? protein combination in treatment of a novel coronavirus infection | |
| JP2023540591A (ja) | 全身性コルチコステロイドによる治療を受けているｃｏｐｄ患者におけるウイルス誘導性増悪を治療するための吸入インターフェロン－ベータの使用 | |
| CN116472054A (zh) | 用于改善SARS-CoV-2感染患者的预后的吸入型干扰素-β | |
| Barnes | Chemokines in COPD | |
| Kushal | Six Minute Walk Test in COPD and Its Correlation with Spirometry and Echocardiography |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20161121 |